Pompano Beach, Fla., May 21, 2014 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, today announced it has appointed Dr. Brijeshkumar Patel, PhD to the newly created position of Director of Research and Development. In this role Dr. Patel will focus on the development of transdermal drug delivery systems for the Company's hair-care products, as well as restructuring existing and new molecules for increased absorption and effectiveness. He will work alongside a team of chemists both within DS Healthcare and with the Company's external consultants to develop skin-care applications. In addition to maintaining the highest quality controls for the Company's over-the-counter formulations, Dr. Patel will also collaborate with Aptiv Solutions, DS Healthcare's clinical research organization (CRO) on the Company's prescription-grade hair formulation currently under development.
"We are executing on the pursuit of science that enhances hair regrowth and youthful skin. Dr. Patel joins us as Director of R&D to lead our clinical development efforts for both our prescription hair loss development program and our portfolio of over-the-counter hair care and skin care products," stated DS Healthcare President and CEO Daniel Khesin. "We've seen demand for our over-the-counter products continue to grow based on the performance of our proprietary, patent-pending formulations. With Dr. Patel on our team, we believe we will be in a position to accelerate our innovation and clinical programs with a goal towards expanding our intellectual property, product portfolio and corresponding revenues."
Dr. Patel has over 7 years of research experience in developing novel drug delivery systems for pulmonary, oral and topical delivery of small molecules and peptide drugs. He brings to DS Healthcare specific expertise in designing preclinical and clinical study protocols. He has authored 10 articles published in peer-reviewed scientific publications and delivered over a dozen poster and oral presentations at scientific conferences. Dr. Patel received his Ph.D. in Pharmaceutical Sciences from the Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center. He also earned his M.S. in Pharmaceutical Sciences from the School of Pharmacy, Campbell University, and his B.S. in Pharmaceutical Sciences from the Shri B M Shah College of Pharmaceutical Education and Research, HNGU, India.
DS Healthcare Group recently announced its intention to file an Investigational New Drug application with the U.S. Food and Drug Administration for a topical hair loss treatment. If approved, it would be the third FDA-approved treatment for hair loss and only the second topical treatment. The Company has recently filed two patents for its prescription and over-the-counter hair loss formulations.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group's flagship brand, visit www.dslaboratories.com
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov .
Laurel Moody Corporate Profile 1.646.810.0608
